Find a Clinical Trial

Find a Clinical Trial

Use the abbreviation for your state (ie. FL, TX, NV)
Search by trial titles, indicators and specific disease types.

Lymphomas

Clinical Trial at: Arizona Oncology - Phoenix

A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223,CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

  • Details

ClinicalTrials.gov ID: NCT02031419
Diagnosis Type: NA
USOR Number: 13092

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, AZ 85016
P: (602) 277-4868

More Details View Practice Page

Lymphomas

Clinical Trial at: Arizona Oncology - Phoenix

A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223,CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

  • Details

ClinicalTrials.gov ID: NCT02031419
Diagnosis Type: NA
USOR Number: 13092

  • Practice Details

19646 N 27th Avenue, Suite 406
Phoenix, AZ 85027
P: (602) 357-2400

More Details View Practice Page

Lymphomas

Clinical Trial at: Arizona Oncology - Phoenix

Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001)

  • Details

ClinicalTrials.gov ID: NCT02555878
Diagnosis Type: Non-Hodgkins
USOR Number: 15026

  • Practice Details

19646 N 27th Avenue, Suite 406
Phoenix, AZ 85027
P: (602) 357-2400

More Details View Practice Page

Leukemia

Clinical Trial at: Arizona Oncology - Phoenix

(UTX-TGR-204) A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

  • Details

ClinicalTrials.gov ID: NCT02656303
Diagnosis Type: CLL
USOR Number: 16213

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, AZ 85016
P: (602) 277-4868

More Details View Practice Page

Leukemia

Clinical Trial at: Arizona Oncology - Phoenix

A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208)

  • Details

ClinicalTrials.gov ID: NCT02717611
Diagnosis Type: CLL
USOR Number: 15222

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, AZ 85016
P: (602) 277-4868

More Details View Practice Page

Leukemia

Clinical Trial at: Arizona Oncology - Phoenix

(UTX-TGR-204) A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

  • Details

ClinicalTrials.gov ID: NCT02656303
Diagnosis Type: CLL
USOR Number: 16213

  • Practice Details

19646 N 27th Avenue, Suite 406
Phoenix, AZ 85027
P: (602) 357-2400

More Details View Practice Page

Leukemia

Clinical Trial at: Arizona Oncology - Phoenix

A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208)

  • Details

ClinicalTrials.gov ID: NCT02717611
Diagnosis Type: CLL
USOR Number: 15222

  • Practice Details

19646 N 27th Avenue, Suite 406
Phoenix, AZ 85027
P: (602) 357-2400

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Arizona Oncology - Phoenix

A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

  • Details

ClinicalTrials.gov ID: NCT02872714
Diagnosis Type: NA
USOR Number: 15228

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, AZ 85016
P: (602) 277-4868

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Arizona Oncology - Phoenix

A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

  • Details

ClinicalTrials.gov ID: NCT02872714
Diagnosis Type: NA
USOR Number: 15228

  • Practice Details

19646 N 27th Avenue, Suite 406
Phoenix, AZ 85027
P: (602) 357-2400

More Details View Practice Page

Leukemia

Clinical Trial at: Arizona Oncology - Phoenix

(UTX-TGR-304) Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)

  • Details

ClinicalTrials.gov ID: NCT02612311
Diagnosis Type: CLL
USOR Number: 15229

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, AZ 85016
P: (602) 277-4868

More Details View Practice Page

Breast Cancer

Clinical Trial at: Arizona Oncology - Phoenix

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer.(INO-VT-464-CL-006)

  • Details

ClinicalTrials.gov ID: NCT02580448
Diagnosis Type: NA
USOR Number: 16010

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, AZ 85016
P: (602) 277-4868

More Details View Practice Page

Myelomas

Clinical Trial at: Arizona Oncology - Phoenix

Daratumumab plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects with Multiple Myeloma (54767414MMY2012)

  • Details

ClinicalTrials.gov ID: NCT02951819
Diagnosis Type: NA
USOR Number: 16084

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, AZ 85016
P: (602) 277-4868

More Details View Practice Page

Myelomas

Clinical Trial at: Arizona Oncology - Phoenix

Daratumumab plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects with Multiple Myeloma (54767414MMY2012)

  • Details

ClinicalTrials.gov ID: NCT02951819
Diagnosis Type: NA
USOR Number: 16084

  • Practice Details

19646 N 27th Avenue, Suite 406
Phoenix, AZ 85027
P: (602) 357-2400

More Details View Practice Page

Breast Cancer

Clinical Trial at: Arizona Oncology - Phoenix

Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (ONT-380-206)

  • Details

ClinicalTrials.gov ID: NCT02614794
Diagnosis Type: NA
USOR Number: 16195

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, AZ 85016
P: (602) 277-4868

More Details View Practice Page

Lymphomas

Clinical Trial at: Arizona Oncology - Phoenix

Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001)

  • Details

ClinicalTrials.gov ID: NCT02555878
Diagnosis Type: Non-Hodgkins
USOR Number: 15026

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, AZ 85016
P: (602) 277-4868

More Details View Practice Page

Breast Cancer

Clinical Trial at: Arizona Oncology - Phoenix

Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (ONT-380-206)

  • Details

ClinicalTrials.gov ID: NCT02614794
Diagnosis Type: NA
USOR Number: 16195

  • Practice Details

19646 N 27th Avenue, Suite 406
Phoenix, AZ 85027
P: (602) 357-2400

More Details View Practice Page

Lymphomas

Clinical Trial at: Arizona Oncology - Phoenix

SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, AZ 85016
P: (602) 277-4868

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Arizona Oncology - Phoenix

A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

  • Details

ClinicalTrials.gov ID: NCT02872714
Diagnosis Type: NA
USOR Number: 15228

  • Practice Details

19646 N 27th Avenue, Suite 406
Phoenix, AZ 85027
P: (602) 357-2400

More Details View Practice Page

Breast Cancer

Clinical Trial at: Arizona Oncology - Phoenix

(USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer

  • Details

ClinicalTrials.gov ID: NCT02187991
Diagnosis Type: NA
USOR Number: 13033

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, AZ 85016
P: (602) 277-4868

More Details View Practice Page

Cervical Cancer

Clinical Trial at: Arizona Oncology - Phoenix

Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001)

  • Details

ClinicalTrials.gov ID: NCT02555878
Diagnosis Type: NA
USOR Number: 15026

  • Practice Details

19646 N 27th Avenue, Suite 406
Phoenix, AZ 85027
P: (602) 357-2400

More Details View Practice Page

Pages